Total Cost Structure for Medical Device Market Entry in Israel

1. Key takeaways

With government fees at zero, the cost of entering the Israeli market consists of six categories: IRH holding service fees, SII testing fees, translation and localisation fees, notarisation and legalisation fees, product liability insurance, and clinical evaluation and expert opinion fees (only where there is no reference-country approval). The first five are routine items; the sixth is pathway-specific. GRZAN’s principle is that every amount that belongs to a commercial quotation is marked as a practical estimate and never mixed with official figures; a budget table should clearly separate the two columns of officially verifiable items and market-priced items.

• Government fees are 0 (since August 15, 2022); the remaining costs sit on the services side.
• Five cost categories are routine; clinical evaluation and expert opinions apply only when no reference-country approval exists.
• Verifiable official parameters include the 120-day standard review, the 45/60-working-day fast track, the 48-hour declaration route, and validity limits of 5 years (3 years for implants).
• Recurring costs are the most commonly omitted line: IRH annual fees, import permit renewal, annual declarations, insurance and ISO certificate maintenance.
• Budgeting over a first-certification-plus-three-year-maintenance window captures most products’ full cycle.
• Annual declarations apply to Class I and Class A IVD and recur every year, so they belong on the recurring side of the table.

2. Legal basis

The cost structure is driven by specific statutory requirements, each of which generates a cost line even though the government itself charges nothing. The table below maps the cost drivers to their legal sources. Regulatory information was verified as of October 29, 2026 against official Israeli legal databases and authoritative public sources; AMAR procedural documents are updated frequently, so the current version on the Israeli Ministry of Health website governs before formal submission.

3. Expert insights

Classifying costs by whether they can be verified is more useful than ranking them by size, because the two classes behave differently in a budget.

Verifiable items (official figures). Government fees are 0 (since August 15, 2022). The standard-path review takes 120 days; the fast track takes 45 or 60 working days; the declaration route takes 48 hours. Registration validity is capped at 5 years, with 3 years for implants. These figures can be cited directly in any internal business case.

Conditional costs (product-dependent). SII testing is required for active electrical products and not required for non-active products. Apostille or consular legalisation depends on the document type and the current administrative position. Clinical evaluation and opinions from two experts arise only where there is no reference-country approval. Each of these lines should be switched on or off after a product-specific determination, not copied from a template.

Recurring costs (calculated per year). These include the IRH annual service fee, import permit renewal, annual declarations (Class I and Class A IVD), product liability insurance, and ISO certificate maintenance. This category is the one most often left out of budgets: companies tend to count only the one-time investment in obtaining the certificate, yet the annual maintenance cost of an Israeli project represents a non-trivial share of total lifecycle cost (practical estimate).

In project budgeting GRZAN uses a first certification plus three years of maintenance basis rather than looking at the first year alone. The reason is arithmetic: registration validity is capped at 5 years, implants at 3 years, and Class I renews annually. A three-year window therefore covers the complete cycle for the majority of products and exposes the recurring costs that a first-year view would hide.

A practical way to populate the two columns is to start from the statutory parameters and work outward. The legal basis section above already fixes the verifiable figures; the remaining work is to collect dated, itemised quotations for each conditional and recurring item from named service providers. A quotation that bundles all six categories into one figure cannot be audited or renegotiated later, so the itemisation requested at quotation stage determines the quality of the budget for its whole life. When a conditional item such as SII testing or legalisation is later found not to apply, its line simply drops out of the right-hand column without disturbing the rest of the model.

4. Practical recommendations

• Split the budget table into two columns. Officially verifiable items on the left, market-priced items on the right; never mix the two.
• Calculate over a three-year window. Combine the first certification with three years of maintenance to avoid underestimating recurring costs.
• Let SKU count drive localisation cost. Three-language labels and instructions for use are priced per SKU; grouped submissions (Part 18 of this guide) can reduce cost significantly.
• Budget the no-reference-country scenario separately. The investment in clinical evaluation and two expert opinions should be assessed as its own line item (Part 16 of this guide).

5. Verification checklist

• □ The budget table distinguishes officially verifiable items from market-priced items
• □ All six cost categories have been listed item by item, with none omitted
• □ Recurring costs have been calculated over a three-year window
• □ Whether SII testing and notarisation or legalisation are required has been determined for the product
• □ Clinical evaluation and expert opinions for the no-reference-country scenario have been budgeted separately
• □ SKU count and submission unit design have been aligned to optimise localisation cost

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Israeli market. Our team coordinates local importer arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com